Adjuvant Nivolumab vs Observation in Resected Non–Small Cell Lung Cancer Research Summary
The study’s objective was to determine whether adjuvant nivolumab improves disease-free and overall survival among patients with resected non–small cell lung cancer (NSCLC) who completed standard adjuvant chemotherapy or radiotherapy.
Original Source
Read the full article at Jamanetwork →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.